Expectation bias in rheumatoid arthritis clinical trials. The anti‐CD4 monoclonal antibody experience
Open Access
- 1 November 1996
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 39 (11), 1773-1780
- https://doi.org/10.1002/art.1780391102
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- THERAPEUTIC MONOCLONAL ANTIBODIESRheumatology, 1995
- A randomized, double‐blind, placebo‐controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritisArthritis & Rheumatism, 1995
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Chimeric cd4 monoclonal antibody cm‐t412 as a therapeutic approach to rheumatoid arthritisArthritis & Rheumatism, 1993
- Treatment with anti‐cd4 monoclonal antibody and acute interstitial nephritisArthritis & Rheumatism, 1993
- Use of a chimeric monoclonal anti‐CD4 antibody in patients with refractory rheumatoid arthritisArthritis & Rheumatism, 1993
- Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T151. Clinical results and immunopharmacologic effects in an open study, including repeated administrationArthritis & Rheumatism, 1991
- Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibodyArthritis & Rheumatism, 1991
- Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.The Journal of Experimental Medicine, 1985
- Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.The Journal of Experimental Medicine, 1985